Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: the VITdAL-ICU randomized clinical trial.

IMPORTANCE Low vitamin D status is linked to increased mortality and morbidity in patients who are critically ill. It is unknown if this association is causal. OBJECTIVE To investigate whether a vitamin D3 treatment regimen intended to restore and maintain normal vitamin D status over 6 months is of health benefit for patients in ICUs. DESIGN, SETTING, AND PARTICIPANTS A randomized double-blind, placebo-controlled, single-center trial, conducted from May 2010 through September 2012 at 5 ICUs that included a medical and surgical population of 492 critically ill adult white patients with vitamin D deficiency (≤20 ng/mL) assigned to receive either vitamin D3 (n = 249) or a placebo (n = 243). INTERVENTIONS Vitamin D3 or placebo was given orally or via nasogastric tube once at a dose of 540,000 IU followed by monthly maintenance doses of 90,000 IU for 5 months. MAIN OUTCOMES AND MEASURES The primary outcome was hospital length of stay. Secondary outcomes included, among others, length of ICU stay, the percentage of patients with 25-hydroxyvitamin D levels higher than 30 ng/mL at day 7, hospital mortality, and 6-month mortality. A predefined severe vitamin D deficiency (≤12 ng/mL) subgroup analysis was specified before data unblinding and analysis. RESULTS A total of 475 patients were included in the final analysis (237 in the vitamin D3 group and 238 in the placebo group). The median (IQR) length of hospital stay was not significantly different between groups (20.1 days [IQR, 11.1-33.3] for vitamin D3 vs 19.3 days [IQR, 11.1-34.9] for placebo; P = .98). Hospital mortality and 6-month mortality were also not significantly different (hospital mortality: 28.3% [95% CI, 22.6%-34.5%] for vitamin D3 vs 35.3% [95% CI, 29.2%-41.7%] for placebo; hazard ratio [HR], 0.81 [95% CI, 0.58-1.11]; P = .18; 6-month mortality: 35.0% [95% CI, 29.0%-41.5%] for vitamin D3 vs 42.9% [95% CI, 36.5%-49.4%] for placebo; HR, 0.78 [95% CI, 0.58-1.04]; P = .09). For the severe vitamin D deficiency subgroup analysis (n = 200), length of hospital stay was not significantly different between the 2 study groups: 20.1 days (IQR, 12.9-39.1) for vitamin D3 vs 19.0 days (IQR, 11.6-33.8) for placebo. Hospital mortality was significantly lower with 28 deaths among 98 patients (28.6% [95% CI, 19.9%-38.6%]) for vitamin D3 compared with 47 deaths among 102 patients (46.1% [95% CI, 36.2%-56.2%]) for placebo (HR, 0.56 [95% CI, 0.35-0.90], P for interaction = .04), but not 6-month mortality (34.7% [95% CI, 25.4%-45.0%] for vitamin D3 vs 50.0% [95% CI, 39.9%-60.1%] for placebo; HR, 0.60 [95% CI, 0.39-0.93], P for interaction = .12). CONCLUSIONS AND RELEVANCE Among critically ill patients with vitamin D deficiency, administration of high-dose vitamin D3 compared with placebo did not reduce hospital length of stay, hospital mortality, or 6-month mortality. Lower hospital mortality was observed in the severe vitamin D deficiency subgroup, but this finding should be considered hypothesis generating and requires further study. TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01130181.

[1]  P. Schlattmann,et al.  Rehabilitation Interventions for Postintensive Care Syndrome: A Systematic Review* , 2014, Critical care medicine.

[2]  O. Franco,et al.  Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies , 2014, BMJ : British Medical Journal.

[3]  I. Reid,et al.  The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. , 2014, The lancet. Diabetes & endocrinology.

[4]  J. Ioannidis,et al.  Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials , 2014, BMJ : British Medical Journal.

[5]  J. D. McNally.  Vitamin D as a modifiable risk factor in critical illness: questions and answers provided by observational studies. , 2014, Jornal de pediatria.

[6]  J. Wetterslev,et al.  Vitamin D supplementation for prevention of mortality in adults. , 2014, The Cochrane database of systematic reviews.

[7]  E. Giovannucci,et al.  Association of Low Serum 25-Hydroxyvitamin D Levels and Sepsis in the Critically Ill , 2014, Critical care medicine.

[8]  Rachel M. Perron,et al.  Efficacy of high-dose vitamin D supplementation in the critically ill patients. , 2013, Inflammation & allergy drug targets.

[9]  A. Berghold,et al.  Correction of vitamin D deficiency in critically ill patients - VITdAL@ICU study protocol of a double-blind, placebo-controlled randomized clinical trial , 2012, BMC Endocrine Disorders.

[10]  D. Viswanath,et al.  Dietary Reference Intakes for Calcium and Vitamin D , 2012, Pediatrics.

[11]  Prevalence of pituitary disorders associated with traumatic brain injury: a systematic review , 2012, Critical Care.

[12]  M. Whiting,et al.  Evaluation of 25-hydroxy vitamin D assay on the immunodiagnostic systems iSYS analyser , 2012, Annals of clinical biochemistry.

[13]  C. Gordon,et al.  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.

[14]  E. Giovannucci,et al.  Association of low serum 25-hydroxyvitamin D levels and mortality in the critically ill* , 2011, Critical care medicine.

[15]  T. Pieber,et al.  Short-term effects of high-dose oral vitamin D3 in critically ill vitamin D deficient patients: a randomized, double-blind, placebo-controlled pilot study , 2011, Critical care.

[16]  F. Leblond,et al.  Reduced hepatic synthesis of calcidiol in uremia. , 2010, Journal of the American Society of Nephrology : JASN.

[17]  J. Simpson,et al.  Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. , 2010, JAMA.

[18]  J. Eisman,et al.  Vitamin D deficiency in critically ill patients. , 2009, The New England journal of medicine.

[19]  H. Bischoff-Ferrari,et al.  High-dose oral vitamin D3 supplementation in rheumatology patients with severe vitamin D3 deficiency. , 2009, Bone.

[20]  I. Reid,et al.  High-dose oral vitamin D3 supplementation in the elderly , 2009, Osteoporosis International.

[21]  A. Wallace,et al.  A simple automated solid-phase extraction procedure for measurement of 25-hydroxyvitamin D3 and D2 by liquid chromatography-tandem mass spectrometry , 2009, Annals of clinical biochemistry.

[22]  A. Wilmer,et al.  Mini-series: II. Clinical aspects. Clinically relevant CYP450-mediated drug interactions in the ICU , 2009, Intensive Care Medicine.

[23]  B. Boehm,et al.  Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. , 2008, Archives of internal medicine.

[24]  C. Cooper,et al.  Effect of annual intramuscular vitamin D on fracture risk in elderly men and women--a population-based, randomized, double-blind, placebo-controlled trial. , 2007, Rheumatology.

[25]  R. Vieth.  Critique of the considerations for establishing the tolerable upper intake level for vitamin D: critical need for revision upwards. , 2006, The Journal of nutrition.

[26]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[27]  T. Oppé,et al.  Vitamin D deficiency. , 1979, British medical journal.

[28]  P. Autier,et al.  Vitamin D status and ill health: a systematic review. , 2014, The lancet. Diabetes & endocrinology.

[29]  S. Pilz,et al.  Vitamin D deficiency and mortality risk in the general population: a meta-analysis of prospective cohort studies. , 2012, The American journal of clinical nutrition.

[30]  Christine L. Taylor,et al.  Committee to Review Dietary Reference Intakes for Vitamin D and Calcium , 2011 .